Skip to main content
Clinical Trials/IRCT1138901181414N11
IRCT1138901181414N11
Completed
Phase 3

Comparison of the short & long term effects and side effects of Samen recombinant human growth hormone & NOVO growth hormone in children with growth hormone deficiency: double-blind randomized clinical trial study

Pharmacy CO. Samen0 sites22 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Growth hormone deficiency in children.
Sponsor
Pharmacy CO. Samen
Enrollment
22
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Pharmacy CO. Samen

Eligibility Criteria

Inclusion Criteria

  • inclusion criteria:
  • 1\-Pre\-pubertal stage
  • 2\-Height standard deviation score\<\-3
  • 3\-Insulin growth factor\-1 inappropriate for age \& sex (low)
  • 4\-Growth hormone level post stimulating test by clonidine \<10 ng/ml
  • 5\-Rule out of the other causes of growth hormone deficiency
  • exclusion criteria:
  • 1\-Acute disorders such as seizure, infection diseases
  • 2\-Turner syndrome
  • 3\-Chronic kidney disease

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials